Ajanta Pharma, Biocon Partner for Semaglutide in 26 Markets

Ajanta Pharma has forged an in-licensing agreement with Biocon to commercialize semaglutide, a GLP-1 receptor agonist, across 26 countries in Africa, the Middle East, and Central Asia. This strategic partnership is expected to significantly boost Ajanta Pharma's growth, leveraging the expanding global market for diabetes and weight-loss therapies.

• Ajanta Pharma partnered with Biocon for semaglutide.
• Agreement covers exclusive marketing in 23, semi-exclusive in 3 countries.
• Semaglutide targets type-2 diabetes and weight management.
• Product launch expected post 2026 patent expiry, regulatory approvals.
• Deal forecasts significant sales for Ajanta Pharma by FY28.
• Collaboration expands Biocon's global GLP-1 portfolio footprint.

Read the full story on Quick Digest.